Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02570022 · ClinicalTrials.gov registry record · Phase 4
Liposomal Bupivacaine in Total Shoulder Arthroplasty
A Phase 4 study, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Phase 4
- Development phase
- 57
- Enrollment target
NCT02570022 is a Phase 4 study that has completed, run by Henry Ford Health System. The registered enrollment target is 57 participants.
The verdict
NCT02570022, a Phase 4 study, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 57 participants
- Enrollment target
Study Summary
This is a randomized, single blinded, standard of care controlled clinical trial. All adult patients over eighteen desiring shoulder arthroplasty will be eligible. The study compares pain control and opioid consumption in patients undergoing shoulder arthroplasty between patients receiving liposomal bupivacaine and those who underwent a preoperative inter-scalene nerve block.
Interventions
- DRUG Liposomal bupivacaine
- DRUG Ropivacaine
- PROCEDURE Inter-scalene nerve block
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02570022
The ClinicalTrials.gov registry entry for NCT02570022 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Liposomal bupivacaine is the first listed.
NCT02570022 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02570022 about?
NCT02570022 is a clinical study titled "Liposomal Bupivacaine in Total Shoulder Arthroplasty". This is a randomized, single blinded, standard of care controlled clinical trial. All adult patients over eighteen desiring shoulder arthroplasty will be eligible. The study compares pain control and opioid consumption in patients undergoing shoulder arthroplasty between patients receiving liposomal...
What is the current status of trial NCT02570022?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 57 participants. The study started on 2014-10. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02570022?
The interventions under investigation include: Liposomal bupivacaine (DRUG), Ropivacaine (DRUG), Inter-scalene nerve block (PROCEDURE).
Who is sponsoring clinical trial NCT02570022?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.